Clinic Roundup
Raptor Pharmaceutical Corp., of Novato, Calif., completed enrollment in a Phase III study of its delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.